The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Generic semaglutide (the biosimilar version of Ozempic) is running out at pharmacies across Quebec due to recalls and surging demand. If you're currently on this medication or planning to start, here's what the shortage means for your treatment and what alternatives exist.
Singapore has approved Wegovy (semaglutide) as the first medication specifically indicated for MASH with liver fibrosis, a serious liver condition affecting millions globally. This expands the growing body of evidence that GLP-1 medications do far more than help with weight loss. Here is what patients and those considering GLP-1 therapy need to know.
Medicare's GLP-1 coverage program has reached 700,000 seniors, with Eli Lilly capturing roughly 70% of that market. This milestone signals a major shift in how older Americans access weight loss and diabetes medications, but navigating the coverage details still takes work.
Novo Nordisk has filed a lawsuit against Eli Lilly over advertising claims related to their GLP-1 medications. This legal battle between two pharmaceutical giants could affect how patients and pharmacists understand these drugs. Here's what you need to know and why it matters for your treatment decisions.
Hanmi Pharmaceutical is preparing to launch Eppe, a Korean-made GLP-1 weight loss medication that could put real pricing pressure on Wegovy and Mounjaro. Here's what patients currently researching or taking GLP-1 medications should understand about this new competitor and what it might mean for costs.
The European Medicines Agency granted Mounjaro a formal weight management indication, expanding access to tirzepatide for obesity treatment across Europe. If you're considering GLP-1 therapy, here's what this approval means for eligibility, coverage, and your options on both sides of the Atlantic.
Emerging research is exploring whether GLP-1 medications like semaglutide could help treat opioid use disorder, not just obesity. Scientists believe these drugs may reduce cravings by affecting reward pathways in the brain. Here's what the current evidence says and what questions to bring to your doctor.
Novo Nordisk has launched clinical trials testing lower maintenance doses of oral semaglutide (oral Wegovy). This development could expand access and improve tolerability for patients who struggle with injectable GLP-1 medications. Here's what current and prospective patients need to know right now.
